Article Text

Download PDFPDF
Identification of cryptic splice site, exon skipping, and novel point mutations in type I CD36 deficiency
  1. H Hanawa1,
  2. K Watanabe2,
  3. T Nakamura3,
  4. Y Ogawa1,
  5. K Toba1,
  6. I Fuse1,
  7. M Kodama1,
  8. K Kato1,
  9. K Fuse1,
  10. Y Aizawa1
  1. 1First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan
  2. 2Department of Clinical Pharmacology, Niigata College of Pharmacy, Niigata, Japan
  3. 3Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  1. Correspondence to:
 Dr H Hanawa, First Department of Internal Medicine, Niigata University School of Medicine, Asahimachi 1-754, Niigata, 951-8510 Japan;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

CD36 is an 88 kDa glycoprotein IV expressed in platelets, monocytes, erythroblasts, capillary endothelial cells, and mammary epithelial cells.1 CD6 was reported to be a receptor for collagen, thrombospondin, P falciparum infected red blood cells,2 apoptotic neutrophils,3 oxidised low density lipoproteins,4 and as a transporter for long chain fatty acids.5 CD36 serves many functions in coagulation, host defence, lipid metabolism and scavenging. CD36 deficiency was first identified in a patient who showed refractoriness to HLA matched platelet transfusion.6 CD36 deficiency can be divided into two subgroups; in type I neither platelets nor monocytes/macrophages express CD36, and in type II monocytes/macrophages express CD36 but platelets do not.7 CD36 deficiency is more often observed in Japanese, Thais, and Africans than in Americans of European descent.8, 9 The incidence of type II CD36 deficiency is approximately 4.0% in Japanese, whereas type I CD36 deficiency is 0.56%.8 However, approximately 17% of Japanese patients with coronary heart disease have CD36 deficiency10 and 40% of Japanese patients with HCM with asymmetrical hypertrophy (ASH) have CD36 deficiency.11 It has been reported that CD36 deficiency might easily result in ischaemic heart disease10 and hypertrophic cardiomyopathy (HCM).11

Recently, CD36 has been reported to play an important role in atherogenicity. It was reported that CD36 deficiency could promote defective insulin action and disordered fatty acid metabolism in spontaneous hypertension12, 13 and antidiabetic thiazolidinedione drug and peroxisome proliferator activated receptor-γ (PPAR-γ) regulated CD36 expression.14, 15 To understand the role of CD36, it is important to clarify the condition of CD36 deficient subjects.

Kashiwagi et al16 and Yanai et al17 reported three mutations responsible for CD36 deficiency, a substitution of T for C at nt 478 of CD36 cDNA, a dinucleotide deletion at nt 539, …

View Full Text